Navigation Links
BRAF inhibitor treatment causes melanoma cells to shift how they produce energy
Date:3/8/2013

A multi-institutional study has revealed that BRAF-positive metastatic malignant melanomas develop resistance to treatment with drugs targeting the BRAF/MEK growth pathway through a major change in metabolism. The findings, which will be published in Cancer Cell and have been released online, suggest a strategy to improve the effectiveness of currently available targeted therapies.

"We were surprised to find that melanoma cells treated with the BRAF inhibitor vemurafenib dramatically change the way they produce energy to stay alive," says David E. Fisher, MD, PhD, chief of Dermatology at Massachusetts General Hospital (MGH) and a co-corresponding author of the Cancer Cell paper. "While current BRAF inhibitor treatment is a major improvement shrinking tumors in most patients and extending survival for several months patients eventually relapse. So there is an ongoing need to improve both the magnitude and durability of these responses."

In about half the cases of malignant melanoma the most deadly form of skin cancer tumor growth is driven by mutations in the BRAF gene. Research by investigators at the MGH Cancer Center and elsewhere has shown that treatment with drugs that block BRAF activity temporarily halts tumor growth. Combining a BRAF inhibitor with a drug that targets MEK, another protein in the same growth pathway, strengthens and extends the antitumor response. The current study was designed to investigate how BRAF inhibition changes metabolic activity within melanoma cells and to find other possible treatment targets.

The most common way that cells convert glucose into energy is called oxidative phosphorylation and largely relies on the activity of the cellular structures called mitochondria. Many cancer cells use an alternative mechanism that produces the energy compound ATP without involving mitochondria. A series of experiments by the MGH team revealed that the elevated BRAF activity in BRAF-positive m
'/>"/>

Contact: Michelle Marcella
mmarcella@partners.org
617-724-2755
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
2. VyGone Inhibitor Zapper: The Brand New Solution For the Safe Treatment Of Sores, Warts and Herpes
3. Inhibitors of shuttle molecule show promise in acute leukemia
4. Leukemia inhibitory factor may be a promising target against pancreatic cancer
5. Uncommon BRAF mutation in melanoma sensitive to MEK inhibitor drug therapy
6. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
7. PARP inhibitors may have clinical utility in HER2-positive breast cancers
8. New mechanism of action for PARP inhibitors discovered
9. PI3-kinase and PARP inhibitor combo may offer new treatment option for triple-neg breast cancers
10. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
11. New small molecule inhibitor could be a safe and first-line treatment for metastatic breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Chicago, Illinois (PRWEB) August 27, 2014 ... integration project in the US with Buzz™ Digital O.R. ... The foundation of all 13 new operating rooms will ... control and management. This integrative system supports planning, navigation, ... is an advanced fusion of intuitive software and hardware ...
(Date:8/27/2014)... August 27, 2014 SCOTT Sports ... Park, Utah’s first indoor mountain bike and BMX park. ... park-style bikes in both adult and youth sizes for the ... operated a distribution warehouse in Ogden, Utah, recently moved its ... , “We are proud to be a partner with the ...
(Date:8/27/2014)... Steven Reinberg HealthDay Reporter ... hormone used to reduce the need for blood transfusions might ... suggests. Synthetic erythropoietin (EPO), which stimulates red blood cell ... preterm birth, said lead researcher Dr. Petra Huppi, a professor ... in Switzerland. "The real test of whether EPO protects ...
(Date:8/27/2014)... microGUNE, the Co-operative Research Centre into Microtechnologies, ... to generate innovative solutions based on microtechnologies ... industry and life sciences, among others. IK4-Ikerlan, ... are collaborating with CIC microGUNE on this ... by the Etortek 2013-2014 programme of the ...
(Date:8/27/2014)... water and oil and are persistent towards aggressive ... characteristics have made the fluorochemicals useful in numerous ... paper and board. , The problem with fluorochemicals ... and accumulate in both humans and the environment. ... effects, such as cancer, increased cholesterol and a ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:SCOTT Sports to Sponsor Wasatch Indoor Bike Park 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3Health News:Microtechnologies for driving forward mobility and human health 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3
... many aren,t getting preventive treatments , , THURSDAY, Jan. ... patients in hospitals worldwide risk developing dangerous blood ... receiving treatments that could prevent the condition, a ... long been recognized to be one of the ...
... NEW YORK, Jan. 31 QED International Associates, ... 20 underlying,indexes for the HealthShares(TM) Exchange-Traded Funds, today ... Monday February 4, 2008,BioMerieux Worldwide (Euronext: BIM) will ... European Medical Products and Devices Index., Companies ...
... But analysis calls gap between these and lower-tier facilities ... admitted to the top-rated hospitals in the United States ... than patients admitted to other hospitals in the country, ... an independent health-care ratings organization, the analysis of 27 ...
... Set for February 29, 2008, PALO ALTO, ... JAZZ ) announced today that the U.S. Food ... submission of the,response by Solvay Pharmaceuticals, Inc. to ... maleate) Extended-Release Capsules. The,FDA has notified Solvay Pharmaceuticals ...
... N.J., Jan. 31 Medarex, Inc.,(Nasdaq: MEDX ) ... the,Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device,Conference at ... event will be,webcast live and will be available in ... http://www.medarex.com . An archived edition of the,presentation will ...
... Jan. 31 Acura,Pharmaceuticals, Inc. (OTC Bulletin Board: ... Market(R) has approved the Company,s application to,list its ... The,Company,s common stock will commence trading on NASDAQ ... "We are pleased to join the growing ...
Cached Medicine News:Health News:Hospital Patients' Blood Clot Risk High 2Health News:Hospital Patients' Blood Clot Risk High 3Health News:Top-Rated Hospitals Continue to Deliver Better Care 2Health News:Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR 2Health News:Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2
(Date:8/26/2014)... BLUE BELL, Pa. , Aug. 26, 2014 ... PRA Health Sciences, largest office worldwide. PRA, a leading global Contract ... and Fort Washington locations into ... . The new office opened this week and marks the ... an exciting time for us at PRA," said Harris Koffer ...
(Date:8/26/2014)... , Aug. 26, 2014 Biomedical Research ... has been named to the prestigious 2014 Inc. 500 ... honored to be included on this prestigious list and ... Chris Jacob , Biomedical Research Laboratories, CEO. "Today,s ... further serves to validate the hard work and talent ...
(Date:8/26/2014)... , Aug. 26, 2014 ... of the "Global Veterinary Diagnostics Market 2014-2018" ... Veterinary diagnostics include various tests, which are used ... livestock producers, and biomedical researchers are mainly availing ... testing (Deoxyribonucleic Acid/Ribonucleic Acid testing), immunodiagnostics, clinical chemistry, ...
Breaking Medicine Technology:PRA Health Sciences Expands in Pennsylvania 2Biomedical Research Laboratories Named to Inc. 500 List of America's Fastest-Growing Companies 2Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 2Global Veterinary Diagnostics Market 2014-2018: Key Vendors are Abaxis, Heska, IDEXX Laboratories, Mindray Medical, VCA Antech and Zoetis 3
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
... Small Volume Medication Mouthpiece 7FT O 2 ... advanced jet design for fast treatment times , ... a tighter distribution (higher percentage of respirable particles) ... AirLife™ brand Misty Max 10™ disposable nebulizers deliver ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: